105 related articles for article (PubMed ID: 18058538)
21. Distinct modulation of telomere length in two T-lymphoblastic leukemia cell lines by cytotoxic nucleoside phosphonates PMEG and PMEDAP.
Hájek M; Cvilink V; Votruba I; Holý A; Mertlíková-Kaiserová H
Eur J Pharmacol; 2010 Sep; 643(1):6-12. PubMed ID: 20599933
[TBL] [Abstract][Full Text] [Related]
22. Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins.
Naasani I; Seimiya H; Tsuruo T
Biochem Biophys Res Commun; 1998 Aug; 249(2):391-6. PubMed ID: 9712707
[TBL] [Abstract][Full Text] [Related]
23. Telomerase inhibitors identified by a forward chemical genetics approach using a yeast strain with shortened telomere length.
Nakai R; Ishida H; Asai A; Ogawa H; Yamamoto Y; Kawasaki H; Akinaga S; Mizukami T; Yamashita Y
Chem Biol; 2006 Feb; 13(2):183-90. PubMed ID: 16492566
[TBL] [Abstract][Full Text] [Related]
24. Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells.
Gomez-Millan J; Goldblatt EM; Gryaznov SM; Mendonca MS; Herbert BS
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):897-905. PubMed ID: 17175117
[TBL] [Abstract][Full Text] [Related]
25. Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells.
Akiyama M; Hideshima T; Shammas MA; Hayashi T; Hamasaki M; Tai YT; Richardson P; Gryaznov S; Munshi NC; Anderson KC
Cancer Res; 2003 Oct; 63(19):6187-94. PubMed ID: 14559802
[TBL] [Abstract][Full Text] [Related]
26. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells.
Chen Z; Koeneman KS; Corey DR
Cancer Res; 2003 Sep; 63(18):5917-25. PubMed ID: 14522918
[TBL] [Abstract][Full Text] [Related]
27. Irreversible telomere shortening by 3'-azido-2',3'-dideoxythymidine (AZT) treatment.
Gomez DE; Tejera AM; Olivero OA
Biochem Biophys Res Commun; 1998 May; 246(1):107-10. PubMed ID: 9600076
[TBL] [Abstract][Full Text] [Related]
28. Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro.
Hayakawa N; Nozawa K; Ogawa A; Kato N; Yoshida K; Akamatsu Ki; Tsuchiya M; Nagasaka A; Yoshida S
Biochemistry; 1999 Aug; 38(35):11501-7. PubMed ID: 10471302
[TBL] [Abstract][Full Text] [Related]
29. [Inhibition of telomeres and telomerase. Seeking for new anticancer drugs].
Raymond E; Faivre S; Dieras V; Von Hoff D
Bull Cancer; 1997 Dec; 84(12):1123-33. PubMed ID: 9587365
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of human telomerase by nucleotide analogues bearing a hydrophobic group.
Yamaguchi T; Kawarai M; Takeshita Y; Ishikawa F; Saneyoshi M
Nucleic Acids Symp Ser; 2000; (44):175-6. PubMed ID: 12903325
[TBL] [Abstract][Full Text] [Related]
31. Consequences of telomerase inhibition by BIBR1532 on proliferation and chemosensitivity of chondrosarcoma cell lines.
Parsch D; Brassat U; Brümmendorf TH; Fellenberg J
Cancer Invest; 2008 Jul; 26(6):590-6. PubMed ID: 18584350
[TBL] [Abstract][Full Text] [Related]
32. Identification of a quinoxaline derivative that is a potent telomerase inhibitor leading to cellular senescence of human cancer cells.
Kim JH; Kim JH; Lee GE; Kim SW; Chung IK
Biochem J; 2003 Jul; 373(Pt 2):523-9. PubMed ID: 12689331
[TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents.
Cookson JC; Dai F; Smith V; Heald RA; Laughton CA; Stevens MF; Burger AM
Mol Pharmacol; 2005 Dec; 68(6):1551-8. PubMed ID: 16150933
[TBL] [Abstract][Full Text] [Related]
34. Effects of cisplatin on telomerase activity and telomere length in BEL-7404 human hepatoma cells.
Zhang RG; Zhang RP; Wang XW; Xie H
Cell Res; 2002 Mar; 12(1):55-62. PubMed ID: 11942411
[TBL] [Abstract][Full Text] [Related]
35. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
Kelland LR
Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
[TBL] [Abstract][Full Text] [Related]
36. Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss.
Ji HJ; Rha SY; Jeung HC; Yang SH; An SW; Chung HC
Breast Cancer Res Treat; 2005 Oct; 93(3):227-36. PubMed ID: 16132531
[TBL] [Abstract][Full Text] [Related]
37. Telomerase inhibitors in cancer therapy: current status and future directions.
Incles CM; Schultes CM; Neidle S
Curr Opin Investig Drugs; 2003 Jun; 4(6):675-85. PubMed ID: 12901225
[TBL] [Abstract][Full Text] [Related]
38. Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro.
Hao Z; Cooney DA; Hartman NR; Perno CF; Fridland A; DeVico AL; Sarngadharan MG; Broder S; Johns DG
Mol Pharmacol; 1988 Oct; 34(4):431-5. PubMed ID: 2459590
[TBL] [Abstract][Full Text] [Related]
39. Telomerase and cancer.
Harley CB; Kim NW
Important Adv Oncol; 1996; ():57-67. PubMed ID: 8791128
[TBL] [Abstract][Full Text] [Related]
40. Oligonucleotide N3'-->P5' phosphoramidates as efficient telomerase inhibitors.
Herbert BS; Pongracz K; Shay JW; Gryaznov SM
Oncogene; 2002 Jan; 21(4):638-42. PubMed ID: 11850790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
